487 related articles for article (PubMed ID: 19338264)
1. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble DA; Loewe R; Yu P; Mihm MC
Cancer Immun; 2009 Apr; 9():3. PubMed ID: 19338264
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
Lee N; Zakka LR; Mihm MC; Schatton T
Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
[TBL] [Abstract][Full Text] [Related]
3. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
4. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4
Mastracci L; Fontana V; Queirolo P; Carosio R; Grillo F; Morabito A; Banelli B; Tanda E; Boutros A; Dozin B; Gualco M; Salvi S; Romani M; Spagnolo F; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2020 Apr; 69(4):653-662. PubMed ID: 32025849
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
Schatton T; Scolyer RA; Thompson JF; Mihm MC
Methods Mol Biol; 2014; 1102():287-324. PubMed ID: 24258985
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.
Mansfield PF; Rosenblum MG; Murray JL; Itoh K
Cancer Immunol Immunother; 1991; 33(4):247-54. PubMed ID: 1829394
[TBL] [Abstract][Full Text] [Related]
8. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma.
Maibach F; Sadozai H; Seyed Jafari SM; Hunger RE; Schenk M
Front Immunol; 2020; 11():2105. PubMed ID: 33013886
[TBL] [Abstract][Full Text] [Related]
10. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M; Randriamampita C; Maubec E; Badoual C; Fouquet S; Wang SF; Marinho E; Farhi D; Garcette M; Jacobelli S; Rouquette A; Carlotti A; Girod A; Prévost-Blondel A; Trautmann A; Avril MF; Bercovici N
J Invest Dermatol; 2011 Jun; 131(6):1300-7. PubMed ID: 21346771
[TBL] [Abstract][Full Text] [Related]
11. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
12. Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.
Shitaoka K; Hamana H; Kishi H; Hayakawa Y; Kobayashi E; Sukegawa K; Piao X; Lyu F; Nagata T; Sugiyama D; Nishikawa H; Tanemura A; Katayama I; Murahashi M; Takamatsu Y; Tani K; Ozawa T; Muraguchi A
Cancer Immunol Res; 2018 Apr; 6(4):378-388. PubMed ID: 29475880
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 blockade boosts the expansion of tumor-reactive CD8
Friese C; Harbst K; Borch TH; Westergaard MCW; Pedersen M; Kverneland A; Jönsson G; Donia M; Svane IM; Met Ö
Sci Rep; 2020 Mar; 10(1):3914. PubMed ID: 32127601
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex.
Sinnamon AJ; Sharon CE; Song Y; Neuwirth MG; Elder DE; Xu X; Chu EY; Ming ME; Fraker DL; Gimotty PA; Karakousis GC
J Am Acad Dermatol; 2018 Aug; 79(2):245-251. PubMed ID: 29518458
[TBL] [Abstract][Full Text] [Related]
15. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
16. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes.
Su Y; Jackson EK; Gorelik E
Cancer Immunol Immunother; 2011 Jan; 60(1):111-22. PubMed ID: 20960188
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic Differences in Tumor-Infiltrating Lymphocytes and Neovascularization Between Primary Cutaneous Melanoma With and Without Metastasis: An Immunohistochemical Study of 80 Cases.
Salgüero I; Roustán G; Requena L; Suárez D; García-Fresnadillo D; Redondo JI; Nájera L
Am J Dermatopathol; 2021 Nov; 43(11):811-818. PubMed ID: 33534211
[TBL] [Abstract][Full Text] [Related]
18. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
19. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
